Health Canada approves CERVARIX(TM), new GSK cervical cancer vaccine
Shown to provide the longest protection against cervical cancer
MISSISSAUGA, ON,
"In
CERVARIX(TM) has the longest duration of protection reported for any licensed cervical cancer vaccine(2). It is the only vaccine that has demonstrated that virtually all women tested still have protective antibodies against both HPV 16 and 18 up to 6.4 years.(3)
CERVARIX(TM) contains a unique adjuvant system, AS04, which has been added to the vaccine to improve the immune response by providing stronger and longer protection as compared with a traditional adjuvant.(4) Duration of protection is particularly important as almost all women are at risk of HPV infection and cervical cancer throughout their lives.
CERVARIX(TM) has shown protection beyond HPV 16 and HPV 18. GSK's Phase III clinical trial, which included over 18,000 women, evaluated the efficacy of HPV types 16 and 18 as well as other cancer causing HPV types. In this trial several subsets of women were analyzed. In one analysis CERVARIX(TM) demonstrated protection against HPV type 45 in addition to types 16 and 18. In another, CERVARIX(TM) demonstrated protection against HPV type 31 in addition to types 16 and 18.(5) HPV types 45 and 31 are the third and fourth leading causes of cervical cancer.(6)
"When it comes to preventing cervical cancer, woman have to be very diligent," said
CERVARIX(TM) is effective against CIN1 (cervical lesions) caused by HPV-16 and 18.(7) These lesions contribute to approximately 325,000 abnormal Paps every year in
CERVARIX(TM) is now approved in over 100 countries around the world. To date ten million doses have been distributed globally.
CERVARIX(TM) is generally well tolerated. The most common local adverse reactions and general adverse events in (greater than or equal to)20% of subjects were pain, redness, and swelling at the injection site, fatigue, headache, myalgia, gastrointestinal symptoms, and arthralgia.
About cervical cancer
Women are at risk of HPV infection and cervical cancer throughout their lives and it is estimated that more than two million women who could be getting vaccinated are not taking advantage.(8)
- Approximately one woman loses her life every 20 hours in spite of
regular Pap screening programs. Vaccination alongside regular Pap
screening is critically important because it could reduce the risk of
developing cervical cancer caused by HPV-16 and 18 by 98 per cent,
compared to no intervention.(9)
- 99 per cent of women age 10 to 25 could benefit from a cervical
cancer vaccine.(10)
- Annually 1,450 (one every 6 hours) Canadian women will be diagnosed
with cervical cancer.(11)
- As many as 80 per cent of women will be infected with HPV in their
lifetime.(12)
- Up to 60 per cent of women will be infected with cancer causing types
in their lifetime.(13, 14)
- Among Canadian women aged 20-44, cervical cancer incidence ranks
second only to breast cancer.(15)
- Cervical cancer is a major health, psychological and social burden on
women everywhere.
- Approximately four million Pap tests are done every year in Canada.
About 8 per cent (over 325,000) have abnormal results.(16)
Approximately 100 types of human papillomavirus have been identified to date and, of these, approximately 15 virus types are considered to cause cervical cancer.(17,18 19)
About GlaxoSmithKline
GlaxoSmithKline Inc. - one of the world's leading research-based pharmaceutical, vaccine and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In
CERVARIX(TM) is a trademark, used under license by GlaxoSmithKline Inc.
Video News Release will be available via satellite on
Tuesday, February 9th at 10:00 - 10:30 and again at 2:00 - 2:30 Eastern
Anik F2, C-Band, Transponder 3B @111.1 West
Vertical Polarization, D/L Freq. 3820MHz.
Audio subcarriers 6.8 left, 6.2 right
FOR ASSISTANCE WITH THE FEED CALL: 1-800-565-1471
Notes for editors:
Clinical trial information:
Health Canada's approval follows a review of data from clinical trials which involved almost 30,000 women and which evaluated efficacy, immunogenicity and safety data. The file included:
- Data from the largest Phase III cervical cancer vaccine efficacy
trial to date called HPV 008 PATRICIA (PApilloma TRIal Cervical
cancer In young Adults)(20)
- This multi-centre, double-blind, randomized study that involved
a total of 18,644 women, aged between 15 and 25 years, from 14
countries across Europe, Asia-Pacific and Latin and North
America
- This study assessed the efficacy of CERVARIX(TM)in the
prevention of precancerous lesions and efficacy against 6 and
12 month persistent infection and High grade pre-cancerous
lesions caused by HPV-16 or HPV-18 or other cancer-causing
virus types as well as immunogenicity and safety,
- Study participants were randomized to receive either
CERVARIX(TM) or a control hepatitis A vaccine and analyses were
performed in the following cohorts:
- According-to-protocol cohort for efficacy (ATP;
vaccine=8093; control=8069)
- Total vaccinated cohort (TVC; vaccine=9319,
control=9325)
- ATP included all women who met eligibility criteria, complied
with the trial protocol and received all three doses of study
vaccine
- TVC included all women who received at least one vaccine dose.
This group comprised a diverse population of women including
those with evidence of current or previous HPV infection and
with high grade smear test results. This was intended to
represent a real world, general population of sexually active
young women(1)
- Data from a long term Phase II efficacy study of CERVARIX(TM)(21)
- The primary study was a double-blind, controlled trial of
1,113 young women between 15-25 years of age, randomized to
receive three doses of CERVARIX or three doses of placebo on a
0, 1 and 6 month schedule.
- This study was conducted in the US, Canada and in Brazil and
evaluated the efficacy, safety and immunogenicity of
CERVARIX(TM) for the prevention of HPV-16 and or HPV-18
infections as well as associated Pap smear abnormalities and
cervical lesions.
- This extended follow-up study looked at study endpoints for
776 women from the same cohort of women for a period of up to
76 months.
Statements about Cervical Cancer Vaccination
--------------------------------------------
In
The new CERVARIX(TM) studies demonstrate a wider spectrum of coverage of cancer-causing HPV types, raising the potential for even greater cancer protection and reinforcing the role of vaccination in the prevention of cervical cancer and precursor lesions.
At the present time, vaccination combined with regular Pap testing offers the optimal approach to prevention of cervical cancer.
Marie Plante, MD, FRCSC
President
The Society of Gynecologic Oncology of Canada
In
The Society of Canadian Colposcopists welcomes an additional vaccine that can protect women against this deadly cancer.
The Society of Canadian Colposcopists
The Federation of Medical Women of
The Federation of Medical Women of Canada
"Each year, approximately 580 Canadian women die of cervical cancer, with thousands more receiving the diagnosis. Women are dying needlessly from this largely preventable disease. CERVARIX(TM) is a welcomed addition to Canada's arsenal in the fight against HPV and cervical cancer."
Dr. Michel Fortier,
President of the Society of Obstetricians and Gynaecologists of
Canada.
References
-------------------------------
(1) CERVARIX Product Monograph
(2) Romanowski B et al. Lancet 2009;374: 1975
(3) Romanowski B et al. Lancet 2009;374: 1975
(4) Giannini SL, et al. Enhanced humoral and memory B cellular immunity
using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminum salt
combination (AS04) compared to aluminum salt only. Vaccine 2006 24:
5937-5949
(5) Paavonen J, et al. Lancet 2009; 374:301-314
(6) Munoz N, et al. Int J Cancer 2004; 111:278-285
(7) CERVARIX Product Monograph
(8) GSK Data on file
(9) Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX,
Franco E. Projected clinical benefits and cost-effectiveness of a
human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004b; 96:
604-615. 13.
(10) Paavonen J, Naud P, Romanowski B, Aoki F MD. Efficacy of human
papillomavirus 16/18 AS04-adjuvanted vaccine against cervical
infection and precancer caused by oncogenic HPV types. The Lancet,
2009; 374: 301-314.
(11) Kulasingam et al , Human papillomavirus testing with Pap triage for
cervical cancer prevention in Canada: a cost-effectiveness analysis
BMC Medicine 2009, 7:69
(12) Tjalma et al, Role of Human papillomavirus in the carcinogenesis of
Squamous cell carcinoma and Adenocarcinoma of the cervix. Best Pract
Res Clin Obstet Gynaecol , 2005, 19(4):469-483
(13) Cuschieri KS, Cubie HA, Whitley MW et al. Multiple high risk HPV
infections are common in cervical neoplasia and young women in a
cervical screening population. J Clin Pathol 2004; 57: 68-72.
(14) Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and
neoplasia in a large population-based prospective study: The
Manchester cohort. Br J Cancer 2004; 91: 942-953.
(15) Cancer in Young Adults in Canada 2006, Cancer Care Ontario and the
Public Health Agency of Canada. Last accessed on November 10, 2009.
http://www.cancer.ca/Canada-wide/About cancer/Cancer statistics/~/media/CCS/
Canada wide/Files List/English files heading/Library PDFs - English/
Cancer in young adults in Canada - completed PDF - English_1252681884.ashx
(16) Canadian Women's Health Network
http://www.cwhn.ca/resources/faq/abnormalPap.html Last accessed on
October 21, 2009
(17) Peto J, et al. Cervical HPV infection and neoplasia in a large
population-based prospective study: The Manchester cohort. Br J
Cancer 2004; 91: 942-53.
(18) de Villiers E, et al. Classification of papillomavirus. Virology
2004; 324: 17-27
(19) Wain G, The human papillomavirus (HPV) vaccine, HPV related diseases
and cervical cancer in the post-reproductive years,Maturitas in
press 2009
(20) Paavonen J, et al. Lancet 2009; 374:301-314
(21) Romanowski B et al. Lancet 2009;374: 1975
For further information: or to arrange an interview, please contact: Sarah Rutka, for GSK, Direct: (416) 645-8191, Cell: (647) 291-1058, [email protected]; GlaxoSmithKline, Corporate Communications, (905) 819-3363
Share this article